Do not use LONQUEX:
- if you are hypersensitive (allergic) to lipegfilgrastim or any of the other ingredients of LONQUEX (listed in section 6)
Warnings and precautions:
Tell your doctor or healthcare provider before being given the injection: Special care should be taken with LONQUEX:
- If you are allergic to any other medicine of the group of G - CSFs (e.g. filgrastim, lenograstim or pegfilgrastim). There could be a risk of reacting to LONQUEX too
- if you have a history of blood cancers
- if you get left upper abdominal pain or pain at the tip of your shoulder. It could be a consequence of a spleen disorder (see POSSIBLE SIDE EFFECTS)
- if you have a cough, fever and difficulty breathing. It could be a consequence of a pulmonary disorder (see POSSIBLE SIDE EFFECTS)
- if you have symptoms of swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These could be symptoms of "capillary leak syndrome"
- if you have sickle cell anaemia, which is an inherited disease characterised by sickle - shaped red blood cells.
Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported rarely with other medicines like this one (e.g. filgrastim, lenograstim or pegfilgrastim of the group of G - CSFs). The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience these symptoms.
A precancerous condition called myelodysplastic syndrome (MDS) or a type of blood cancer called acute myeloid leukaemia (AML) have been reported with pegfilgrastim, a medicine like LONQUEX, when used in combination with chemotherapy and/or radiotherapy in breast and lung cancer patients. Although these conditions have not yet been reported with LONQUEX, your doctor will monitor you for signs and symptoms of MDS/AML, which may include tiredness, fever, and easy bruising or bleeding.
Your doctor will carry out regular blood tests in order to monitor various blood components and their levels. Your doctor will also check your urine regularly as other medicines similar to this one (e.g. other granulocyte colony stimulating factors such as filgrastim, lenograstim or pegfilgrastim) can possibly harm the tiny filters inside your kidneys (glomerulonephritis; see POSSIBLE SIDE EFFECTS).
Children and adolescents:
Do not give LONQUEX to children and adolescents under 18 years of age because there is only limited experience in children to show that LONQUEX is safe and works in this age group.
Other medicines and LONQUEX:
Always tell your healthcare provider if you are taking any other medicine. (This includes complementary or traditional medicines.)
You will normally inject your dose of LONQUEX approximately 24 hours after your last dose of chemotherapy at the end of each chemotherapy cycle.
Pregnancy, breastfeeding and fertility:
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, please consult your doctor, pharmacist or other healthcare provider for advice before receiving LONQUEX.
Pregnancy: The safety and efficacy of LONQUEX has not been established in pregnant women.
Breastfeeding: It is unknown whether the LONQUEX passes into the breast milk. You should therefore interrupt breastfeeding your baby, during treatment.
Fertility: No data available with respect to fertility.
Driving and using machines:
It is not known whether LONQUEX has an effect on you being able to drive or use any tools or machines. It is not always possible to predict to what extent LONQUEX may interfere with the daily activities of a patient. Patients should ensure that they do not engage in driving a vehicle or use machines until they are aware of the measure to which LONQUEX affects them.
LONQUEX contains sugar (sorbitol): Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) receive LONQUEX.
LONQUEX contains less than 1 mmol sodium (23 mg) per pre - filled syringe, that is to say essentially sodium - free.